Theravance (TBPH) Fundamental Analysis: Revenue, Earnings & Valuation

3.26 / 10

Netural

Fundamental analysis scores 3.3/10, indicating weak fundamentals. Interest coverage and Asset‑MV are positive, yet long‑term debt to working capital, revenue growth, and total operating revenue are poor, resulting in a cautious outlook.

Analysis Checks(6/10)

Revenue-MV

Value-1.08

Score1/3

Weight18.97%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value66.92

Score1/3

Weight-1.50%

1M Return-0.38%

Inventory turnover ratio

Value103.94

Score2/3

Weight-4.36%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value20.28

Score3/3

Weight7.10%

1M Return1.67%

PB-ROE

Value0.86

Score2/3

Weight35.64%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value0.40

Score1/3

Weight-2.57%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.43%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value66.92

Score1/3

Weight-1.18%

1M Return-0.30%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-4.19%

1M Return-1.13%

Asset-MV

Value-0.55

Score2/3

Weight56.50%

1M Return11.12%

Is TBPH fundamentally strong?

TBPH scores 3.26/10 on fundamentals and holds a Fair valuation at present. Backed by its 44.85% ROE, 98.54% net margin, 7.91 P/E ratio, 2.82 P/B ratio, and 282.61% earnings growth, these metrics solidify its Netural investment rating.